Vaxcyte Q1 net loss $39M, cash $352M; VAX-24 topline results due end-2022

Vaxcyte, Inc.

2023-Q1 EPS reported -$0.68

Q1 net loss $39.0M vs $21.2M YoY; R&D $31.7M, G&A $7.5M.
Cash, cash equivalents and investments $352.3M at March 31, 2022, including $107.6M net from public offering.
VAX-24 Phase 1/2 study dosing in both phases; topline safety, tolerability, immunogenicity results expected by year-end 2022.
Separate VAX-24 Phase 2 study in adults 65+ expected to start mid-2022; topline results expected H1 2023.
Appointed Mikhail Eydelman as SVP, General Counsel & Corporate Secretary in April 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.